News

The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint — a significant reduction in the number of new lesions visible on a brain imaging scan — in a Phase 2 trial in people with multiple sclerosis (MS), study results show. SAR442168,…

A way of detecting the density of proteins in the blood, called “magnetic levitation” or MagLev, may aid in more quickly diagnosing chronic diseases, including the particular type of multiple sclerosis suspected in a person, the scientists who developed this method report. Plasma, the liquid component of blood, is composed of…

The immune signaling molecule interleukin-17A (IL-17A) promotes the recruiting of inflammatory cells to the central nervous system (brain and spinal cord) in a multiple sclerosis (MS) mouse model, a study found. The findings support the potential of therapies that target IL-17 in MS. IL-17A is part of the IL-17…

Changing a person’s diet to reduce the amount of methionine (amino acid found in food) could delay the development and progression of inflammatory and autoimmune disorders, including multiple sclerosis (MS). That finding was described in the study “…

Having other health conditions, or comorbidities, along with multiple sclerosis (MS) does not increase a person’s risk of being hospitalized due to MS-specific symptoms, although it does raise the rate of all-cause hospital admissions, a study found.  The finding was described…

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for QyScore, a cloud-based imaging software for the automated quantification of key magnetic resonance imaging (MRI) markers of central nervous system (CNS) disease. MRI is an important tool for diagnosing multiple sclerosis and other CNS disorders. By…

Transplanting patients’ own mesenchymal stem cells (MSCs) is a safe therapeutic approach and can delay disease progression in people with multiple sclerosis (MS), a meta-analysis review shows. The study also showed that cells transplanted to the spinal cord (intrathecal injection) were associated with significantly slower disease progression rates, compared…

People with multiple sclerosis (MS) have a more diverse set of immune cells in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, but no such diversity is seen in their blood, a study reports. Instead, MS causes changes in the activation of immune cells in…

Scientists discovered new interaction between immune cells from the central nervous system (CNS) — consisting of the brain and spinal cord — and immune cells from the blood that may lead to new treatments for multiple sclerosis (MS) and other neurological diseases.

The Multiple Sclerosis Association of America (MSAA) is celebrating 50 years of work and dedication to improving the lives of people affected by multiple sclerosis (MS). Some changes are underway and initiatives being launched to commemorate this milestone. MSAA, a nonprofit organization founded in 1970, aims to provide…

EyeStat, a portable device to measure blink reflex, has been cleared for use by the U.S. Food and Drug Administration (FDA). On the heels of promising results for assessing brain injury, the manufacturer, Blinktbi, plans to test if the device can be used for the early detection…

Harvard professor and scientist Francisco Quintana, PhD, has been awarded the 2019 Barancik Prize for Innovation in MS Research for his work in understanding what causes multiple sclerosis (MS), and how to stop its development. Quintana has developed innovative research programs that use cutting-edge technology to help…

Kevin Schaefer hadn’t been in an airport since he was 4 years old, so he had been looking forward to flying from his home in Cary, North Carolina, to Anaheim, California, in June for the 2019 Cure SMA Conference. As it turned out, his experience didn’t go as expected.

Interaction between various Epstein-Barr virus traits and the composition of certain genes affects the risk of developing multiple sclerosis (MS), a study reports. The study, “The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis,” was published in the journal…

Age, gender, disease subtype, degree of disability, and more factors affect lower urinary tract symptoms (LUTS) among patients with multiple sclerosis (MS). Also, the epidemiology of LUTS must be better understood and promptly detected and treated to improve patients’ quality of life. Those findings are detailed in a new study, “…

Caring for children with multiple sclerosis (MS) can affect the mental health of their mothers over the long term, a study has found. The study, “Increased mental health care use by mothers of children with multiple sclerosis,” was published in the journal Neurology. People with…

The U.S. Food and Drug Administration (FDA) has agreed to allow Myeliviz, an imaging agent of myelin — the protective layer that covers nerve fibers and is damaged in multiple sclerosis (MS) — to be evaluated in a clinical trial with healthy volunteers. Myeliviz, created by Case Western Reserve University researchers, has the potential…

Nerve impulses travel in a “dual cable” with myelin, playing additional roles to what was previously thought, new research has found. This discovery advances human knowledge of how brain connections work, and may help scientists understand more accurately what happens when myelin is lost — which is what occurs…

A psychologist at Swinburne University of Technology in Melbourne has been awarded an incubator grant by MS Research Australia to identify ways to better detect and treat depression in people with multiple sclerosis (MS). The grant given to Lisa Grech, PhD, with the School of Health Sciences at Swinburne, is…

People living close to major roads or highways are at a greater risk of multiple sclerosis (MS), a database study of people in metropolitan Vancouver reports. Parks and other green spaces in urban areas that might lower exposure to air pollutants did not affect a person’s overall risk of developing MS,…

The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion of Plegridy (peginterferon beta-1a) to treat relapsing-remitting multiple sclerosis (RRMS) in England within the National Health Service (NHS). This decision follows a cost-effectiveness review done in May 2018,…

Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS) regardless of a person’s vitamin D levels, a study found. The study, “BMI and low vitamin D are causal factors for multiple sclerosis,” was published in…

Mayzent (siponimod), an approved oral therapy for active secondary progressive multiple sclerosis (SPMS), promotes a more regulatory immune system, which may explain its added benefits for SPMS, new clinical data show. The study “Siponimod enriches regulatory T and B lymphocytes in secondary progressive multiple sclerosis” was published in the…

People with multiple sclerosis (MS) who complete training through a method called the modified Story Memory Technique (mSMT) show a decrease in brain activity after training, which could indicate more efficient brain processing, a recent study shows. The study, “Brain activation patterns associated with paragraph…

Early research in animal models and human samples reveals how loss of communication between nerve cells contributes to the symptoms of multiple sclerosis (MS), and shows how gene therapy could be used to preserve such connections and protect against vision loss. Researchers say their work identifies a…

Since being diagnosed with multiple sclerosis (MS) 20 years ago, Kathy Miska’s ability to walk has steadily worsened, especially in recent years. As a participant of a pilot study at the Cleveland Clinic Mellen Center for Multiple Sclerosis, however, she is cheered by the effect of…

A new study has found a link between the amount of fat in the blood and changes to the arteries surrounding the necks and skulls of people with multiple sclerosis (MS). The finding was described in the study “Lipoprotein(a) Levels Are Associated with the…

The European Commission has approved Novartis‘s Mayzent (siponimod) as the first oral treatment for adults with active secondary progressive multiple sclerosis (SPMS). Active SPMS is defined by the presence of evident relapses or the detection of inflammatory activity in brain lesions on imaging scans. “As the only indicated oral therapy proven for…

The United States Patent and Trademark Office (USPTO) has issued a patent to Endonovo Therapeutics for Application No. 15/549,748, which covers the company’s technique and device for electromagnetic treatment of multiple sclerosis (MS). Endonovo has a pipeline of “Electroceuticals” — wearable, electronic, non-invasive therapeutic devices. These devices…

MedRhythms is planning to soon open a pilot clinical trial to assess the safety and efficacy of its MR-004, its investigational product that uses rhythmic sounds to improve walking abilities in people with multiple sclerosis (MS), the company announced. The randomized and controlled trial, fully support by a grant…